Representative approaches include the combination of 5-aza-2-deoxycytidine or histone deacetylase (HDAC) inhibitors with cytotoxic anti-cancer drugs or with antiviral drugs such as GCV [26,27]. This evidence concerns the gene HDAC9 and cancer.